Silencing TUFM Inhibits Development of Monocrotaline-Induced Pulmonary Hypertension by Regulating Mitochondrial

Ruyuan Wei1, Xin Lv1, Changcun Fang1,2

  • 1Cheeloo College of Medicine, Shandong University, Jinan City, Shandong Province, 250012, China.

Insights

TUFM protein knockdown mitigates pulmonary arterial hypertension (PAH) by inhibiting PASMC proliferation and regulating mitophagy via the AMPK/mTOR pathway. This suggests TUFM as a potential therapeutic target for PAH.

Area of Science:

  • Cardiovascular Biology
  • Mitochondrial Medicine
  • Cellular Pathophysiology

Background:

  • Pulmonary arterial hypertension (PAH) is a severe cardiovascular disease driven by pulmonary arterial smooth muscle cell (PASMC) proliferation.
  • Mitochondria are crucial in PAH pathogenesis, influencing hypoxia sensing, energy metabolism, and apoptosis.
  • TUFM, a mitochondrial protein, is implicated in mitophagy, apoptosis, and oxidative stress, processes relevant to PAH.

Purpose of the Study:

  • To investigate the role of TUFM in the development of pulmonary arterial hypertension (PAH).
  • To explore the underlying molecular mechanisms by which TUFM influences PAH pathogenesis, particularly concerning mitophagy and cell signaling pathways.

Main Methods:

  • TUFM expression was analyzed in monocrotaline (MCT)-induced PAH rat models and PASMCs.
  • TUFM knockdown (Sh-TUFM) and overexpression (OE-TUFM) models were established in rats and PASMCs.
  • Hemodynamic and morphological changes, protein levels (P62, Bax, LC3II/I, BECN1, Bcl2), and AMPK/mTOR signaling were assessed under normoxic and hypoxic conditions.

Main Results:

  • TUFM expression was elevated in PASMCs of MCT-induced PAH rats.
  • TUFM knockdown in rats significantly reduced pulmonary arterial pressure and altered arteriolar morphology compared to PAH controls.
  • TUFM modulation affected key proteins involved in mitophagy and apoptosis, with knockdown promoting mitophagy and inhibiting PASMC proliferation, while overexpression had opposing effects. AMPK/mTOR pathway phosphorylation was altered by TUFM levels.

Conclusions:

  • TUFM plays a significant role in the pathogenesis of MCT-induced pulmonary arterial hypertension.
  • TUFM knockdown inhibits PAH development, likely by promoting mitophagy and modulating the AMPK/mTOR signaling pathway.
  • Targeting TUFM may offer a novel therapeutic strategy for treating pulmonary arterial hypertension.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
247